BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $6.96 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,780 shares of the company’s stock after selling 2,134 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in IDEXX Laboratories were worth $6,962,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of IDXX. Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of IDEXX Laboratories by 151.3% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 85,927 shares of the company’s stock valued at $43,412,000 after acquiring an additional 51,728 shares during the last quarter. Verition Fund Management LLC raised its position in shares of IDEXX Laboratories by 20.5% in the third quarter. Verition Fund Management LLC now owns 6,508 shares of the company’s stock valued at $3,288,000 after purchasing an additional 1,108 shares during the period. Icon Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $264,000. Rockefeller Capital Management L.P. boosted its holdings in shares of IDEXX Laboratories by 0.9% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 52,744 shares of the company’s stock worth $26,650,000 after buying an additional 448 shares during the period. Finally, Vinva Investment Management Ltd grew its stake in IDEXX Laboratories by 12.5% in the 3rd quarter. Vinva Investment Management Ltd now owns 3,469 shares of the company’s stock valued at $1,775,000 after buying an additional 385 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.0 %

NASDAQ IDXX opened at $421.75 on Monday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The stock’s 50 day moving average is $451.91 and its two-hundred day moving average is $477.31. The company has a market capitalization of $34.54 billion, a price-to-earnings ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.53 earnings per share. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.11% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IDXX shares. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Piper Sandler restated a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays lowered their target price on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.